Active clinical trials for "Arteriosclerosis"

To assess the associations of serum sex hormones with the presence and progression of subclinical atherosclerosis.

To evaluate common genetic variations, that in combination with exposure to tobacco smoke, may modify the risk of atherosclerosis.

To rescan 6,700 subjects in the MESA study to obtain computed tomography measures of calcification.

To investigate the prevalence and prognostic value of subclinical atherosclerosis in the Pittsburgh SHEP cohort and a cohort of normal controls.

To determine whether an impairment of myocardial perfusion reserve is an early indicator of coronary artery disease.

To determine the role of genetic factors in predicting resistance and susceptibility to coronary artery disease.

To determine the relative risk in a defined population of angiographically demonstrated coronary artery disease due to genetic polymorphisms at the four apolipoprotein genomic regions.

To measure serum concentrations of alpha tocopherol, selenium and all major carotenoids (alpha- and beta- carotene, lutein, (beta-cryptoxanthin and lycopene) in Black and white, male and female, high and low education individuals aged 18-30 in 1985-86. In subsequent renewals additional markers of oxidative stress and endothelial dysfunction have been measured in blood collected 7 to 30 years after baseline.

To examine the appropriateness of angiographic and ultrasound endpoints as predictors of subsequent clinical coronary events. Follow-up data from the Cholesterol Lowering in Atherosclerosis Study (CLAS) were used.

The study will evaluate the effect of Anpl-one SR Tablet on the improvement of symptoms in daily care environments using PAQ.